Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

NCT04507841 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT04507841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04507841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 8, 2021
Completion date
December 31, 2026
Enrollment
67 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer